Towards a clinical use of miRNAs in pancreatic cancer biopsies

@article{Frampton2013TowardsAC,
  title={Towards a clinical use of miRNAs in pancreatic cancer biopsies},
  author={A. Frampton and T. Gall and L. Castellano and J. Stebbing and L. Jiao and J. Krell},
  journal={Expert Review of Molecular Diagnostics},
  year={2013},
  volume={13},
  pages={31 - 34}
}
Evaluation of: Ali S, Saleh H, Sethi S, Sarkar FH, Philip PA. MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer. Br. J. Cancer 107(8), 1354–1360 (2012). Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, despite advances in imaging, surgery and a greater understanding of its molecular biology. Patient outcomes remain poor due to an inability to detect disease early and resistance to anticancer treatments. miRNAs are promised to become ideal… Expand
Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use
TLDR
The evaluated paper provides further evidence for miRNAs as diagnostic biomarkers for detecting dysplastic and malignant change in IPMNs, which may be useful for future clinical decision making. Expand
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.
TLDR
This review will highlight the translational studies demonstrating that microRNAs may soon translate into clinical applications as long-awaited screening tools and therapeutic targets for PDAC. Expand
Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies
TLDR
The feasibility of using fresh EUS-FNAs to establish miRNA-based signatures unique to pancreatic malignant transformation and the potential to enhance risk stratification and selection for surgery are demonstrated. Expand
microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis.
TLDR
Tumoural miR-21 overexpression emerged as an important predictor of poor prognosis after PDAC resection independent of other clinicopathologic factors, including adjuvant chemotherapy use. Expand
Genetic and molecular alterations in pancreatic cancer: Implications for personalized medicine
TLDR
This review aims to summarize recent advances of important genes, proteins, and microRNAs that play a critical role in the pathogenesis of pancreatic cancer, and to provide implications for personalized medicine in Pancreas cancer. Expand
Antiproliferative and Pro-Apoptotic Effects of MiR-4286 Inhibition in Melanoma Cells
TLDR
The results demonstrate that miR-4286 mediates proliferation and apoptosis in melanoma cells, and may represent a novel mechanism underlying these processes. Expand
TARGETING CANCER CELLS: A NEW THERAPY TO CURE CANCER PATIENTS
Cancer is a multifactorial disease and is one of the leading causes of death worldwide. Emerging evidence indicates that impaired cellular energy metabolism is the defining characteristic of nearlyExpand
Early detection of pancreatic cancer: impact of high-resolution imaging methods and biomarkers
TLDR
This publication reviews the recent contribution of HRIMs and biomarkers toward an early diagnosis of PC and recommends procedures to be started without delay and the co-operation between the primary and tertiary medical centers is highly desirable. Expand
The Role of microRNAs in the Gut-Liver Axis
TLDR
This chapter summarizes the current understanding of miRNAs’ expression and interactions in the gut and liver axis, their contribution in normal and pathological conditions and their potential value as diagnostic/prognostic biomarkers and therapeutic targets. Expand
miRNAs and their application in drug-induced liver injury.
TLDR
The major technologies currently used and challenges in miRNA measurement are described and information on major bioinformatics resources available for current miRNA research is provided. Expand
...
1
2
...

References

SHOWING 1-10 OF 21 REFERENCES
microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma
TLDR
Data is presented indicating that miR-10b is upregulated in pancreatic ductal adenocarcinoma and can be used as a diagnostic marker in endoscopic ultrasound-guided fine-needle aspiration biopsies of suspicious pancreatic lesions and may be able to guide neoadjuvant gemcitabine-based chemoradiotherapy and predict metastatic-free survival and overall survival. Expand
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer
TLDR
The feasibility of using archival FFPE cell blocks from FNAs to establish RNA-based molecular signatures unique to pancreatic adenocarcinoma with potential applications in clinical trials for risk stratification, patient selection, and target validation is demonstrated. Expand
MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma
TLDR
In patients with PDACs, lower levels of miR-10b were associated with improved response to multimodality neoadjuvant therapy, likelihood of surgical resection, delayed time to metastasis, and increased survival. Expand
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues.
TLDR
This study is the first to evaluate the diagnostic potential of miRNAs in a clinical setting and has shown that miRNA analysis of pancreatic FNA biopsy samples can aid in the pathologic evaluation of suspicious cases and may provide a new strategy for improving the diagnosis of Pancic diseases. Expand
MicroRNA miR-155 is a biomarker of early pancreatic neoplasia.
TLDR
Aberrant miRNA expression is an early event in the multistage progression of pancreatic cancer, and miR-155 warrants further evaluation as a biomarker for IPMNs in clinical samples. Expand
MicroRNAs Targeting Oncogenes Are Down-Regulated in Pancreatic Malignant Transformation from Benign Tumors
TLDR
Comparing the miRNA expression signatures in pancreatic benign cystic tumors of low and high malignant potential with PDAC revealed 21 miRNAs down-regulated in PDAC compared to SMCA, the most benign lesion that rarely progresses to invasive carcinoma. Expand
Global microRNA expression profiling of microdissected tissues identifies miR‐135b as a novel biomarker for pancreatic ductal adenocarcinoma
TLDR
Pancreatic cell‐specific global miRNA profiles are reported, which offer new candidate miRNAs to be exploited for functional studies in PDAC and provide evidence that miRNas are well‐suited analytes for development of sensitive and specific aid‐in‐diagnosis tests for PDAC. Expand
Expression profiling identifies microRNA signature in pancreatic cancer
TLDR
A microRNA expression signature has been identified that is associated with pancreatic cancer and Aberrant microRNAs may offer new clues to pancreatic tumorigenesis and may provide diagnostic biomarkers for pancreatic adenocarcinoma. Expand
miRNA Biomarkers in Cyst Fluid Augment the Diagnosis and Management of Pancreatic Cysts
Purpose: The diagnosis of pancreatic cystic lesions has increased dramatically. Most are benign, whereas some, such as intraductal papillary mucinous neoplasms (IPMN), represent precursors ofExpand
MicroRNA Expression Aids the Preoperative Diagnosis of Pancreatic Ductal Adenocarcinoma
TLDR
Evaluated microRNA expression in pancreatic resection specimens and fine needle aspiration biopsies found a select panel of miRNAs aids the distinction between pancreatic lesions in cytology specimens, and Pancreatic ductal adenocarcinomas show differential expression ofmiRNAs compared to benign pancreatic lesions. Expand
...
1
2
3
...